<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01652417</url>
  </required_header>
  <id_info>
    <org_study_id>P 110118</org_study_id>
    <secondary_id>AOM 11003</secondary_id>
    <nct_id>NCT01652417</nct_id>
  </id_info>
  <brief_title>Treatment of Renal Sarcoidosis by Methylprednisolone Bolus</brief_title>
  <acronym>CORTICOIDOSE</acronym>
  <official_title>Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal sarcoidosis treatment is based on steroids, but the dose and duration are unknown.
      Despite this treatment, most patients will have chronic kidney disease. From our previous
      studies, the investigators believe that high dose steroids by methylprednisolone bolus will
      improve patient outcome and renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a multicentric, randomized, open trial, the investigators will assess the efficacy of
      methylprednisolone bolus at 15mg/kg/d for 3 days before oral steroids on renal function
      improvement in renal sarcoidosis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with a positive response defined by eGRF better than 100% compared to eGRF prior treatment or a normalization of renal function.</measure>
    <time_frame>3 months after the beginning of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (eGFR, percentage of patients with a eGRF &lt; 60 ml/min/1.73m²)</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-renal manifestations</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arrhythmias and cardiac conduction disease</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fragility fracture</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuro-psychiatric troubles and infections</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of renal and extra-renal relapses.</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of vitamin and calcium deficiencies by blood and urinary dosages</measure>
    <time_frame>1, 3, 6 and 12 months after the beginning of the treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>oral prednisone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone bolus IV 15 mg/kg/d for 3 days.</intervention_name>
    <description>methylprednisolone bolus IV 15 mg/kg/d for 3 days.</description>
    <arm_group_label>methylprednisolone bolus</arm_group_label>
    <other_name>Methylprenisolone Mylan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Acute kidney injury with estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1,73
             m2, defined by an increase of initial value &gt; 25% or an increase of &gt; 30 µmol/l,
             since at least 3 months.

          -  Sarcoidosis diagnostic criteria according to ATS/ERS/WASOG (Am J Respir Crit Care Med
             1999)

          -  Renal biopsy compatible with renal sarcoidosis :

          -  Granulomatosis tubulo-interstitial nephropathy and extra-renal damage of
             histologically proved or suggestive sarcoidosis Or

          -  Tubulo-interstitial nephropathy without granuloma and extra-renal damage of
             histologically proved sarcoidosis

          -  Informed consent

          -  Patients with social security

        Exclusion Criteria:

          -  Corticosteroids greater than 0,25 mg/kg/j prednisone equivalent

          -  Introduction of an immunosuppressant in the month before inclusion

          -  Another cause of renal granulomatosis or tubulo-interstitial nephropathy

          -  Isolated renal damage without extra-renal past or present damage for a sarcoidosis

          -  Chronic renal failure, prior sarcoidosis with eGFR &lt; 30 mL/min/1,73 m2

          -  Acute renal failure from other causes. If hypercalcaemia is greater than 3 mmol/L,
             the correction of any dehydration will systematically salt intake, followed of renal
             function control before inclusion.

          -  Pregnancy, nursing

          -  Tuberculosis

          -  Uncontrolled sepsis

          -  Uncontrolled psychotic state

          -  Hypersensibility to methylprednisolone hemisuccinate

          -  Drugs prescription causing wave burst arrhythmia and/or long QT on ECG
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Jacques Boffa, PU-PH</last_name>
    <phone>+ 33 (0) 1 56 01 60 29</phone>
    <email>jean-jacques.boffa@tnn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Néphrologie et Dialyses, Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques Boffa, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Boffa, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methylprednisolone</keyword>
  <keyword>prednisone</keyword>
  <keyword>renal sarcoidosis treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
